Nanjing Vcare Ranked 10th on the "Top 20 Chinese Pharmaceutical CRO Enterprises in 2022"

2022-12-12

On December 9, 2022, the 2022 High-Quality Development Conference of the Big Health Industry and the 7th China Pharmaceutical R&D and Innovation Summit was grandly launched online. At the opening ceremony, the highly anticipated "2022 Ranking List Series of Chinese Pharmaceutical R&D Strength" in the pharmaceutical industry was ceremoniously released. Nanjing Vcare PharmaTech Co., Ltd. ("Nanjing Vcare") was listed on the "Top 20 Chinese Pharmaceutical CRO Enterprises in 2022" list and ranked 10th. Since 2020, Vcare PharmaTech has been selected into this list for three consecutive years, with its ranking continuously rising, and its comprehensive strength and R&D capabilities have once again been recognized by the industry.

 

 

The "Top 20 Chinese Pharmaceutical CRO Enterprises in 2022" list was strictly selected based on 10 indicators, including the annual total revenue (total operating revenue), annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, staff size, staff size growth, brand awareness, and leading position in sub-sectors, representing the highest level in the pharmaceutical CRO/CDMO industry.

Since its establishment, Nanjing Vcare has always adhered to scientific research and innovation, and has been deeply focusing on the R&D and production services throughout the whole industrial chain and the whole life cycle of chemical drugs. Adhering to the concept of "The better Care, The better Medicines", it has made every effort to build a one-stop CRO/CDMO service platform integrating "chemistry + pharmacy + medicine", and wholeheartedly provided domestic and foreign pharmaceutical enterprises with the whole-process services and integrated solutions for new drug development, such as CMC research, registration, clinical CRO, CDMO/API/ pharmaceutical intermediate supply. In April of this year, Nanjing Vcare completed the acquisition of its subordinate production base - Hubei Tianshu Pharmaceutical Co., Ltd. Through the construction of an advanced production service platform, it effectively achieved synergy between research and production, enriched and improved the whole-industrial-chain services, so as to better empower the innovative development of the pharmaceutical industry.

In the future, Nanjing Vcare will continue to strengthen the construction of the one-stop R&D and production service platform, continuously integrate resources, solidify the capacity building of the technical platform and expand the experimental facilities. Combining the existing industrial layout, industry development and customer needs, it will further deepen the one-stop CRO/CDMO services.

Prev

Nanjing Vcare Assisted Lizhu Pharmaceutical to Obtain the Production Approval Letter of Pantoprazole Sodium for Injection

Next

Nanjing Vcare Obtained the First One - Time Drug Import Approval in Jiangbei New Area after Empowerment by Jiangsu Provincial Market Supervision Bureau